Molecular Partners Ag (MOLN) Retained Earnings (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Retained Earnings of $498254.0 for Q1 2026, up 16.05% year-over-year from $429347.6 in Q1 2025, and up 2.33% quarter-over-quarter from $486929.0 in Q4 2025.
Molecular Partners Ag (MOLN) Retained Earnings (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Retained Earnings for 7 consecutive years, with $498254.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Retained Earnings rose 16.05% year-over-year to $498254.0; the TTM figure through Mar 2026 stood at $498254.0 (up 16.05% YoY), while the FY2025 annual figure was $486929.0, down 99.89% from the prior year.
- Retained Earnings grew to $498254.0 in Q1 2026 per MOLN's latest filing, from $486929.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $439.3 million in Q4 2024 and bottomed at $371922.6 in Q3 2022.
- Historically, Retained Earnings has averaged $141.9 million across 5 years, with a median of $485303.8 in 2025.
- Annual changes were most pronounced in 2025 — Retained Earnings slumped 99.89% — and 2026, when it climbed 16.05%.
- Molecular Partners Ag's Retained Earnings stood at $374.0 million in 2022, then climbed by 10.18% to $412.1 million in 2023, then increased by 6.62% to $439.3 million in 2024, then plunged by 99.89% to $486929.0 in 2025, then increased by 2.33% to $498254.0 in 2026.
- Business Quant data shows MOLN's Retained Earnings at $498254.0 in Q1 2026, $486929.0 in Q4 2025, and $485303.8 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 498,254.02 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 498,254.02 |
| Dec 31, 2025 | 486,929.01 |
| Sep 30, 2025 | 485,303.76 |
| Jun 30, 2025 | 467,615.38 |
| Mar 31, 2025 | 429,347.62 |
| Dec 31, 2024 | 439.34 Mn |
| Sep 30, 2024 | 425,415.40 |
| Jun 30, 2024 | 406.40 Mn |
| Mar 31, 2024 | 419,759.67 |
| Dec 31, 2023 | 412.08 Mn |
| Sep 30, 2023 | 412,538.28 |
| Jun 30, 2023 | 404.14 Mn |
| Mar 31, 2023 | 391,456.53 |
| Dec 31, 2022 | 374.02 Mn |
| Sep 30, 2022 | 371,922.56 |
| Jun 30, 2022 | 371.82 Mn |
| Mar 31, 2022 | 386,108.89 |
| Dec 31, 2021 | 385.01 Mn |
| Sep 30, 2021 | 385,235.86 |
| Dec 31, 2020 | 331.27 Mn |